Potential for Drug Repositioning of Midazolam for Dentin Regeneration

Int J Mol Sci. 2019 Feb 4;20(3):670. doi: 10.3390/ijms20030670.

Abstract

Drug repositioning promises the advantages of reducing costs and expediting approvalschedules. An induction of the anesthetic and sedative drug; midazolam (MDZ), regulatesinhibitory neurotransmitters in the vertebrate nervous system. In this study we show the potentialfor drug repositioning of MDZ for dentin regeneration. A porcine dental pulp-derived cell line(PPU-7) that we established was cultured in MDZ-only, the combination of MDZ with bonemorphogenetic protein 2, and the combination of MDZ with transforming growth factor-beta 1. Thedifferentiation of PPU-7 into odontoblasts was investigated at the cell biological and genetic level.Mineralized nodules formed in PPU-7 were characterized at the protein and crystal engineeringlevels. The MDZ-only treatment enhanced the alkaline phosphatase activity and mRNA levels ofodontoblast differentiation marker genes, and precipitated nodule formation containing a dentinspecificprotein (dentin phosphoprotein). The nodules consisted of randomly orientedhydroxyapatite nanorods and nanoparticles. The morphology, orientation, and chemicalcomposition of the hydroxyapatite crystals were similar to those of hydroxyapatite that hadtransformed from amorphous calcium phosphate nanoparticles, as well as the hydroxyapatite inhuman molar dentin. Our investigation showed that a combination of MDZ and PPU-7 cellspossesses high potential of drug repositioning for dentin regeneration.

Keywords: cell; dentin; drug repositioning; hydroxyapatite; nanoparticle; nanorod.

MeSH terms

  • Animals
  • Bone Morphogenetic Protein 2 / pharmacology
  • Bone Morphogenetic Protein 2 / therapeutic use
  • Cell Line
  • Dentin / drug effects*
  • Dentin / physiology
  • Drug Repositioning*
  • Midazolam / pharmacology*
  • Midazolam / therapeutic use
  • Odontoblasts
  • Regeneration*
  • Swine
  • Transforming Growth Factor beta1 / pharmacology
  • Transforming Growth Factor beta1 / therapeutic use

Substances

  • Bone Morphogenetic Protein 2
  • Transforming Growth Factor beta1
  • Midazolam